Amylyx Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMLX Nasdaq 2830 amylyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Jan 10th, 2025 1:26 pm
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Jan 10th, 2025 12:30 am
Cerus And 2 Other US Penny Stocks With Promising Potential - Jan 6th, 2025 5:07 pm
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer - Jan 6th, 2025 2:00 pm
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? - Dec 30th, 2024 7:52 pm
Amylyx announces design of LUCIDITY clinical trial - Dec 5th, 2024 12:35 pm
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia - Dec 4th, 2024 12:30 pm
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Nov 27th, 2024 2:00 pm
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Nov 9th, 2024 2:56 pm
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Nov 8th, 2024 7:11 am
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call - Nov 8th, 2024 6:33 am
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results - Nov 7th, 2024 12:00 pm
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - Nov 4th, 2024 2:00 pm
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Oct 26th, 2024 1:05 am
October 2024's US Penny Stocks Poised For Growth - Oct 21st, 2024 4:04 pm
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Oct 19th, 2024 3:12 pm
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Oct 18th, 2024 11:34 am
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - Oct 18th, 2024 11:26 am
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Oct 18th, 2024 11:04 am
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Oct 17th, 2024 1:00 pm